A PHASE I/II, OBSERVER-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTI-COUNTRY STUDY TO EVALUATE REACTOGENICITY, SAFETY, IMMUNE RESPONSE, AND EFFICACY OF AN HSV-TARGETED IMMUNOTHERAPY IN HEALTHY PARTICIPANTS AGED 18-40 YEARS OR IN PARTICIPANTS AGED 18-60 YEARS WITH RECURRENT GENITAL HERPES
- Registry ID
- 215336 (TH HSV REC-003)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2024-11-22
- Last update
- 2023-09-11
Conditions
Related clinical trials
- A PHASE IIIB, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRE, LONG-TERM FOLLOW-UP STUDY (ZOE-LTFU) OF STUDIES 110390 AND 113077 (ZOSTER-005/022) TO ASSESS THE PROPHYLACTIC EFFICACY, SAFETY, AND IMMUNOGENICITY PERSISTENCE OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE AND ASSESSMENT OF 1 OR 2 ADDITIONAL DOSES ON A 0 OR 1, 2-MONTH SCHEDULE IN TWO SUBGROUPS OF OLDER ADULTS
- A PHASE IIIB, NON-RANDOMIZED, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRIC CROSS-VACCINATION STUDY TO EVALUATE THE SAFETY OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A TWO-DOSE SCHEDULE TO SUBJECTS WHO PREVIOUSLY RECEIVED PLACEBO IN ZOSTER-006 AND ZOSTER-022 STUDIES
- A PHASE III, RANDOMIZED, DOUBLE BLIND MULTICENTER STUDY, TO EVALUATE CONSISTENCY, IMMUNOGENICITY, SAFETY AND REACTOGENICITY OF 3 LOTS OF GSK BIOLOGICALS' HERPES ZOSTER HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0 AND 2 MONTH SCHEDULE TO ADULTS >50 YEARS OF AGE
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTRE CLINICAL TRIAL TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GSK BIOLOGICAL'S HERPES ZOSTER VACCINE GSK1437173A WHEN CO-ADMINISTERED WITH GSK BIOLOGICALS' QUADRIVALENT INFLUENZA VACCINE FLU-D-QIV (GSK2321138A) VERSUS SEPARATE ADMINISTRATION OF THE TWO VACCINES IN ADULTS AGED 50 YEARS AND OLDER
- "A PHASE III, RANDOMISED, OBSERVER-BLIND, PLACEBO CONTROLLED, MULTICENTRE CLINICAL STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GASK BIOLOGICALS HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0- AND 1- AND 2-MONTHS SCHEDULE TO ADULTS >18 YEARS OF AGE WITH RENAL TRANSPLANT."
View on source registry